Zydus Lifesciences in Focus After US Food and Drug Administration Closes Unit 9 Inspection with Nil Observations

stock will be in focus on February 20, 2026, after the US Food and Drug Administration completed a Pre-Approval Inspection (PAI) at the company’s Unit 9 facility at Zydus Biotech Park in Ahmedabad from February 16–19. The inspection, related to injectable medical devices, was closed with nil observations, indicating no regulatory concerns were raised. The development is seen as a positive compliance signal and may support sentiment around the stock. In terms of price action, the stock has declined 2% over the past week. However, it has gained 2.42% over the past month, while remaining down 1.31% on a year-to-date basis, reflecting mixed near-term performance. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.